Revathy Ramachandran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Revathy Ramachandran has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Fahad R. Ali
Mohammed Bin Rashid University of Medicine and Health Sciences 2 College of Medicine Dubai, United Arab Emirates
14 shared publications - Anna Philpott
Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK
13 shared publications - Daniel Marcos
Departamento de Bioquímica y Biología Molecular y Genética, Facultad de Ciencias, Universidad de Extremadura, Badajoz, Spain
13 shared publications - Evangelia K. Papachristou
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
13 shared publications - Fiona M. Y. Abou Grealy
University of Cambridge 3 Cancer Research UK Cambridge Institute Cambridge, United Kingdom
13 shared publications - Jason S. Carroll
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
13 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Excel file listing the gene ontology terms and genes making up the cell division gene signature.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Excel file listing the gene ontology terms and genes making up the cell division gene signature.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S3. ASCL1 shows enhanced genome-wide chromatin binding in IMR ASCL1 versus BE ASCL1 cell line upon its overexpression.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S3. ASCL1 shows enhanced genome-wide chromatin binding in IMR ASCL1 versus BE ASCL1 cell line upon its overexpression.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S1. ASCL1 overexpression neuronal differentiation and reduced proliferation.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S1. ASCL1 overexpression neuronal differentiation and reduced proliferation.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Key resources table listing commercial kits, reagents and software used in this study.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Key resources table listing commercial kits, reagents and software used in this study.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Excel file listing the gene ontology terms and genes making up the neuronal gene signature.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Excel file listing the gene ontology terms and genes making up the neuronal gene signature.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S6. Overexpression of Cy/RXL mutant or phospho-mutant ASCL1 improves neuronal differentiation of BE cells over wild-type ASCL1.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S6. Overexpression of Cy/RXL mutant or phospho-mutant ASCL1 improves neuronal differentiation of BE cells over wild-type ASCL1.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S2. ASCL1 overexpression induces more transcriptional changes associated with neuronal differentiation in the IMR ASCL1 than BE ASCL1 cell line.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S2. ASCL1 overexpression induces more transcriptional changes associated with neuronal differentiation in the IMR ASCL1 than BE ASCL1 cell line.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S5. CDK1 and CDK2 bind to phosphorylate ASCL1, affecting its binding to the chromatin in BE ASCL1 cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S5. CDK1 and CDK2 bind to phosphorylate ASCL1, affecting its binding to the chromatin in BE ASCL1 cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S4. ASCL1 protein-protein interactome is enriched for regulators of neuronal differentiation in the IMR ASCL1 cell line and cell cycle components in the BE ASCL1 cell line.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Figure S4. ASCL1 protein-protein interactome is enriched for regulators of neuronal differentiation in the IMR ASCL1 cell line and cell cycle components in the BE ASCL1 cell line.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Neuroblastoma is a heterogeneous pediatric cancer arising from developmentally arrested neuronal precursors, in which restoring differentiation offers therapeutic promise. Achaete-scute homolog 1 (ASCL1), a proneural transcription factor, is widely expressed in neuroblastoma and can drive either proliferation or differentiation depending on the cellular context. In this study, we show that distinct MYCN-amplified neuroblastoma cell lines exhibit differing differentiation responses to ASCL1 overexpression. By comparing genome-wide ASCL1 chromatin binding, transcriptional changes, and protein–protein interactions, we found that ASCL1 binds more extensively to neuronal proteins in a cell line that is more susceptible to ASCL1-driven differentiation but associates with cell-cycle regulators in less responsive cells. We show that cyclin-dependent kinase 2 (CDK2)–cyclin A2 bind ASCL1 in less responsive cells, with CDK-mediated phosphorylation of ASCL1 limiting the ability of ASCL1 to drive differentiation. Implications:Our study reveals that context-dependent interactions of ASCL1 with protein partners on the chromatin control its ability to reengage a differentiation program in neuroblastoma.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma
Neuroblastoma is a heterogeneous pediatric cancer arising from developmentally arrested neuronal precursors, in which restoring differentiation offers therapeutic promise. Achaete-scute homolog 1 (ASCL1), a proneural transcription factor, is widely expressed in neuroblastoma and can drive either proliferation or differentiation depending on the cellular context. In this study, we show that distinct MYCN-amplified neuroblastoma cell lines exhibit differing differentiation responses to ASCL1 overexpression. By comparing genome-wide ASCL1 chromatin binding, transcriptional changes, and protein–protein interactions, we found that ASCL1 binds more extensively to neuronal proteins in a cell line that is more susceptible to ASCL1-driven differentiation but associates with cell-cycle regulators in less responsive cells. We show that cyclin-dependent kinase 2 (CDK2)–cyclin A2 bind ASCL1 in less responsive cells, with CDK-mediated phosphorylation of ASCL1 limiting the ability of ASCL1 to drive differentiation. Implications:Our study reveals that context-dependent interactions of ASCL1 with protein partners on the chromatin control its ability to reengage a differentiation program in neuroblastoma.